The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis

Abstract

Annexin A5 (AnxA5) binds to phospholipid bilayers, forming two-dimensional crystals that block the phospholipids from availability for coagulation enzyme reactions. Antiphospholipid (aPL) antibodies cause gaps in the ordered crystallization of AnxA5 which expose phospholipids and thereby accelerate blood coagulation reactions. The aPL antibody-mediated disruption of AnxA5 crystallization has been confirmed on artificial phospholipid bilayers and on cell membranes including endothelial cells, placental trophoblasts and platelets. Recently, we reported that hydroxychloroquine, a synthetic antimalarial drug, can reverse this antibody-mediated process through two mechanisms: (1) by inhibiting the formation of aPL IgG-β2glycoprotein I complexes; and (2) by promoting the formation of a second layer of AnxA5 crystal ‘patches’ over areas where the immune complexes had disrupted AnxA5 crystallization. In another translational application, we have developed a mechanistic assay that reports resistance to AnxA5 anticoagulant activity in plasmas of patients with aPL antibodies. AnxA5 resistance may identify a subset of aPL syndrome patients for whom this is a mechanism for pregnancy losses and thrombosis. The elucidation of aPL-mediated mechanisms for thrombosis and pregnancy complications may open new paths towards addressing this disorder with targeted treatments and mechanistic assays.

Keywords

annexin A5 annexins antiphospholipid antibodies antiphospholipid syndrome pregnancy losses thrombosis

Get full access to this article

View all access options for this article.

References

Rand JH , Wu XX , Quinn AS , Taatjes DJ Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 2008 ; 17: 922-930.

Gerke V. , Moss SE Annexins: from structure to function. Physiol Rev 2002; 82: 331-371.

Mortimer JC , Laohavisit A. , Macpherson N. , et al. Annexins: multifunctional components of growth and adaptation . J Exp Bot 2008; 59: 533-544.

Moss SE , Morgan RO The annexins. Genome Biol 2004; 5: 219.

Reutelingsperger CP , Kop JM , Hornstra G. , Hemker HC Purification and characterization of a novel protein from bovine aorta that inhibits coagulation. Inhibition of the phospholipid-dependent factor-Xa-catalyzed prothrombin activation, through a high-affinity binding of the anticoagulant to the phospholipids . Eur J Biochem 1988; 173: 171-178.

Andree HA , Reutelingsperger CP , Hauptmann R. , et al. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem 1990; 265: 4923-4928.

Tait JF , Gibson D. , Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1989; 264: 7944-7949.

Crumpton MJ , Dedman JR Protein terminology tangle. Nature 1990; 345: 212.

Funakoshi T. , Heimark RL , Hendrickson LE , et al. Human placental anticoagulant protein: isolation and characterization . Biochemistry 1987; 26: 5572-5578.

10.

Tait JF , Sakata M. , McMullen BA , et al. Placental anticoagulant proteins: isolation and comparative characterization four members of the lipocortin family. Biochemistry 1988; 27: 6268-6276.

11.

Mosser G. , Ravanat C. , Freyssinet JM , Brisson A. Sub-domain structure of lipid-bound annexin-V resolved by electron image analysis . J Mol Biol 1991; 217: 241-245.

12.

Voges D. , Berendes R. , Burger A. , et al. Three-dimensional structure of membrane-bound annexin V. A correlative electron microscopy-X-ray crystallography study. J Mol Biol 1994; 238: 199-213.

13.

Reviakine I. , Bergsma-Schutter W. , Brisson A. Growth of protein 2-D crystals on supported planar lipid bilayers imaged in situ by AFM. J Struct Biol 1998; 121: 356-361.

14.

Andree HAM , Stuart MC , Hermens WT , et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-17912.

15.

Morrissey JH , Pureza V. , vis-Harrison RL , et al. Protein-membrane interactions: blood clotting on nanoscale bilayers. J Thromb Haemost 2009; 7(Suppl 1): 169-172.

16.

van Genderen HO , Kenis H. , Hofstra L. , et al. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization . Biochim Biophys Acta 2008; 1783: 953-963.

17.

Krikun G. , Lockwood CJ , Wu XX , et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994; 15: 601-612.

18.

Rand JH , Wu XX , Andree HA , et al. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154-160.

19.

Engen JR , Smithgall TE , Gmeiner WH , Smith DL Identification and localization of slow, natural, cooperative unfolding in the hematopoietic cell kinase SH3 domain by amide hydrogen exchange and mass spectrometry. Biochemistry 1997; 36: 14384-14391.

20.

Wang X. , Campos B. , Kaetzel MA , Dedman JR Annexin V is critical in the maintenance of murine placental integrity . Am J Obstet Gynecol 1999; 180: 1008-1016.

21.

Flaherty MJ , West S. , Heimark RL , et al. Placental anticoagulant protein-I: measurement in extracellular fluids and cells of the hemostatic system. J Lab Clin Med 1990; 115: 174-181.

22.

Cederholm A. , Svenungsson E. , Jensen-Urstad K. , et al. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25: 198-203.

23.

Cederholm A. , Frostegard J.

Annexin A5 multitasking: a potentially novel antiatherothrombotic agent?

Drug News Perspect 2007; 20: 321-326.

24.

Kaburaki J. , Kuwana M. , Yamamoto M. , et al. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus . Am J Hematol 1997; 54: 209-213.

25.

Satoh A. , Suzuki K. , Takayama E. , et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999; 26: 1715-1720.

26.

Sugiura K. , Muro Y. Anti-annexin V antibodies and digital ischemia in patients with scleroderma . J Rheumatol 1999; 26: 2168-2172.

27.

Zammiti W. , Mtiraoui N. , Hidar S. , et al. Antibodies to beta2-glycoprotein I and annexin V in women with early and late idiopathic recurrent spontaneous abortions. Arch Gynecol Obstet 2006; 274: 261-265.

28.

Zammiti W. , Mtiraoui N. , Kallel C. , et al. A case-control study on the association of idiopathic recurrent pregnancy loss with autoantibodies against beta2-glycoprotein I and annexin V. Reproduction 2006; 131: 817-822.

29.

de Laat B. , Derksen RH , Mackie IJ , et al. Annexin A5 polymorphism (-1C->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 1468-1472.

30.

Siaka C. , Lambert M. , Caron C. , et al. Low prevalence of anti-annexin V antibodies in antiphospholipid syndrome with fetal loss. Rev Med Interne 1999; 20: 762-765.

31.

Arai T. , Matsubayashi H. , Sugi T. , et al. Anti-annexin A5 antibodies in reproductive failures in relation to antiphospholipid antibodies and phosphatidylserine. Am J Reprod Immunol 2003; 50: 202-208.

32.

Rand JH , Arslan AA , Wu XX , et al. Reduction of circulating Annexin A5 levels and resistance to Annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol 2006; 194: 182-188.

33.

Esposito G. , Tamby MC , Chanseaud Y. , et al. Anti-annexin V antibodies: are they prothrombotic? Autoimmun Rev 2005; 4: 55-60.

34.

Bozic B. , Irman S. , Gaspersic N. , et al. Antibodies against annexin A5: detection pitfalls and clinical associations. Autoimmunity 2005; 38: 425-430.

35.

Ogawa H. , Zhao D. , Dlott JS , et al. Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities . Am J Clin Pathol 2000; 114: 619-628.

36.

Rand JH , Wu XX , Guller S. , et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566-1572.

37.

Rand JH , Wu XX , Andree HAM , et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a ‘‘lupus procoagulant’’ phenomenon. Blood 1998; 92: 1652-1660.

38.

Rand JH , Wu XX , Quinn AS , et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163: 1193-1200.

39.

Hanly JG , Smith SA Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol 2000; 120: 537-543.

40.

Gaspersic N. , Ambrozic A. , Bozic B. , et al. Annexin A5 binding to giant phospholipid vesicles is differentially affected by anti-beta2-glycoprotein I and anti-annexin A5 antibodies. Rheumatology 2007; 46: 81-86.

41.

Tomer A. Antiphospholipid antibody syndrome: rapid, sensitive, and specific flow cytometric assay for determination of anti-platelet phospholipid autoantibodies . J Lab Clin Med 2002; 139: 147-154.

42.

Tomer A. , Bar-Lev S. , Fleisher S. , et al. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol 2007; 139: 113-120.

43.

de Laat B. , Wu XX , van Lummel M. , et al. Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109: 1490-1494.

44.

de Laat HB , Derksen RH , Urbanus RT , de Groot PG IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis . Blood 2005; 105: 1540-1545.

45.

de Laat B. , Pengo V. , Pabinger I. , et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study . J Thromb Haemost 2009; 7: 1767-1773.

46.

de Laat B. , Derksen RH , van LM , et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916-1924.

47.

Rothfield N. Efficacy of antimalarials in systemic lupus erythematosus. Am J Med 1988; 85: 53-56.

48.

Tsakonas E. , Joseph L. , Esdaile JM , et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group . Lupus 1998 ; 7: 80-85.

49.

Molad Y. , Gorshtein A. , Wysenbeek AJ , et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002; 11: 356-361.

50.

Fessler BJ , Alarcon GS , McGwin G. Jr , et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473-1480.

51.

Wallace DJ

Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?

Arthritis Rheum 1987 ; 30: 1435-1436.

52.

Edwards MH , Pierangeli S. , Liu X. , et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96: 4380-4384.

53.

Espinola RG , Pierangeli SS , Gharavi AE , Harris EN Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies . Thromb Haemost 2002; 87: 518-522.

54.

Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective . Scand J Rheumatol 1996; 25: 191-193.

55.

Erkan D. , Yazici Y. , Peterson MG , et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924-929.

56.

Ruiz-Irastorza G. , Egurbide MV , Pijoan JI , et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577-583.

57.

Tektonidou MG , Laskari K. , Panagiotakos DB , Moutsopoulos HM Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29-36.

58.

Ruiz-Irastorza G. , Ramos-Casals M. , Brito-Zeron P. , Khamashta MA Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; Epub ahead of print.

59.

Rand JH , Wu XX , Quinn AS , et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112: 1687-1695.

60.

Rand JH , Wu XX , Quinn AS , et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2009; Epub ahead of print.

61.

Rand JH , Wu XX , Lapinski R. , et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104: 2783-2790.

62.

Wu XX , Pierangeli SS , Rand JH Resistance to annexin A5 binding and anticoagulant activity in plasmas from patients with the antiphospholipid syndrome but not with syphilis. J Thromb Haemost 2006; 4: 271-273.

63.

Wu XX , Arslan AA , Wein R. , et al. Analysis of circulating annexin A5 parameters during pregnancy: absence of differences between women with recurrent spontaneous pregnancy losses and controls. Am J Obstet Gynecol 2006 ; 195: 971-978.

64.

Lutters BC , Meijers JC , Derksen RH , et al. Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes. J Biol Chem 2001; 276: 3060-3067.

65.

Rand JH , et al. In: Kaushansky K , Lichtman MA , Beutler E , Kipps TJ , Prchal J , Seligsohn U (eds), Williams Hematology, 8th edn.New York: McGraw-Hill ; 2010.